AWARDS & RECOGNITIONS
Biotechnology Venture Readiness Program 2025 by Saudi Biotechnology Accelerator
20 October 2025
Rosetta Omics is proud to announce its selection for the Biotechnology Venture Readiness Program 2025, an initiative led by the Saudi Biotechnology Accelerator. The opportunity arose following a productive exchange at the KSA Pavilion during the BIO International Convention in Boston earlier this year. This milestone marks an important step in Rosetta’s strategic expansion into the GCC and MENA regions, where Saudi Arabia and the UAE serve as key gateways for biotechnology innovation. The Kingdom of Saudi Arabia is undergoing a remarkable transformation, driven by a strong national vision and a growing appetite for innovation in healthcare and life sciences. Programs such as the Biotechnology Venture Readiness Program exemplify this momentum, offering a platform for pioneering biotech companies to engage with the region’s innovation ecosystem. Through the program, Rosetta Omics will work closely with mentors, investors, key opinion leaders (KOLs), and representatives from the Saudi Food and Drug Authority (SFDA – هيئة الغذاء والدواء), alongside other selected founders in the cohort. The program will culminate in a final showcase event in Riyadh, Saudi Arabia, in December 2025, where participants will present to investors, mentors, and key stakeholders from across the biotechnology sector. This milestone reflects Rosetta Omics’ continued commitment to advancing precision healthcare through data-driven biotechnology and fostering strong regional partnerships in support of global innovation.
Rosetta Omics has been selected to join Season 5 of the Pfizer Healthcare Hub France (PHHF)
1 October 2025
It’s official! Rosetta Omics has been selected to join Season 5 of the Pfizer Healthcare Hub France (PHHF) 🚀 — an acceleration program led by Pfizer in partnership with WILCO, and now a leading reference in France’s health innovation ecosystem.
We’re honored to be part of an exceptional cohort alongside BioKortex, Doctoome, Emobot, Pictaderm, and Primaa, six startups, one shared goal: improving patients’ and caregivers’ lives. ❤️🩹
Over the next 9 months, we’ll receive personalized mentorship to amplify our impact and demonstrate how Rosetta Omics’ AI-enabled multiomics platform can support anti-cancer drug developers in discovering new biomarkers, validating targets, and predicting treatment response more accurately. 🧠🧬
At Rosetta Omics, our mission is to revolutionize cancer care through precision medicine. This collaboration with Pfizer and WILCO marks an important milestone on our journey to make that vision a reality. 🌍✨
🎥 Check out the official video in Pfizer’s post below ⬇️
https://lnkd.in/epFgTUfe
Group BPCE Innovation Prize
26 June 2025
🏅 Rosetta Omics is an innovation prize winner 🏆 Out of more than 50 great startup candidates led by ESCP Business School ESCP Alumni, we are happy to win this honorary innovation prize from Groupe BPCE. Thank you ESCP Foundation Blue Factory ESCP AGORA ESCP Student Union and ESCP Business School and all jury members. We are very proud to be a winner of this innovation prize especially that Rosetta Omics was born at ESCP Business School and has been and still receiving a great support from ESCP community. ESCP Executive Education & Business Solutions Jean-Baptiste Say Institute – ESCP Business School. Rosetta Omics will keep innovating and inspiring others to innovate!
Bio Partnering Pass Challenge
Very proud to be among the winners and be part of this amazing delegation of bright french startups. Thank you very much Medicen Paris Region and and Spartners by Servier France and BioLabs France for the opportunity. We appreciate it.
Young Innovative Company (JEI)
13 June 2025
We are very happy to announce that Rosetta Omics has just been officially awarded the status of Young Innovative Company (JEI)! This recognition values our ongoing commitment to research and development, particularly in the fields of precision medicine, oncology, artificial intelligence and multiomics technologies. It reflects our determination to innovate and provide ever more impactful solutions to patients, clinicians and all our partners. This status also opens up attractive tax advantages for our current and future investors, allowing them to benefit from specific tax incentives. The JEI status is a mark of confidence from the French State, rewarding the involvement of our entire team and paving the way for new growth prospects.
Hello Tomorrow’s Deep Tech Pioneers!
13-14 March 2025
We are very happy to announce that Rosetta Omics have been named one of Hello Tomorrow’s Deep Tech Pioneers! 🌍 The email reads : “Congratulations !! We’re excited to announce that your groundbreaking venture, Rosetta Omics, has been selected as one of the esteemed Hello Tomorrow Deep Tech Pioneers! This prestigious recognition marks a pivotal moment in your journey to transform the world through innovation. Out of 4,600 applications from 120 countries, your project distinguished itself as a leading light in deep tech. As a Deep Tech Pioneer, you’ll gain exclusive, year-round access to a wealth of opportunities within our dynamic community”.
HealthTech Innovation Days 1st European Innovation Prize
We are honored and thrilled to announce that Rosetta Omics has won the 1st 🥇 place among a seleted top 20 European companies at the 6th edition of the HealthTech Innovation Days (hashtag#HTIDs) organized by HealthTech For Care in Paris, France. Competing against some of the most innovative companies in Europe, this recognition is a powerful validation of the groundbreaking work we are doing to advance healthcare. We are incredibly grateful for the positive feedback we received from the esteemed jury, composed of top Key Opinion Leaders (KOLs) in healthcare, and the attendees at the event. This award is not just a milestone for our company—it is a testament to the value we’re developing for patients and the broader healthcare ecosystem.
Executive Board Member at Medicen Paris Region!
We are happy to announce that our CEO Dr. Wahid Awad, Ph.D. MBA have been elected as an Executive Board Member (Membre exécutif du conseil administratif) at Medicen Paris Region! Dr. Awad is representing the PME (SMEs) of pharma, biotech, medtech, and diagnostics companies in Paris region ( Île-de-France) in the executive office of Medicen (bureau exécutif). Founded in 2005, the Medicen Paris Region global competitiveness cluster aims to position the Paris Region as a European industrial leader in diagnostic and therapeutic innovation and leading-edge health technologies, thus enabling it to become one of the global centres for translational medicine.
Rosetta Omics Joins the First Cohort of #NextAfrica
February 2025
Rosetta Omics Joins the First Cohort of hashtagNextAfrica!
We are very happy to announce that Rosetta Omics has been selected and joined the inaugural cohort of hashtagNextAfrica acceleration program: An ambitious initiative led by UM6P – University Mohammed VI Polytechnic in partnership with STATION F (the biggest startup campus in the world located in the heart of Paris) and WILCO to bridge Europe and Africa.
This is an incredible opportunity for us to expand our vision of transforming cancer care globally through precision medicine, starting with cancer and leveraging multimodal clinical data coupled with AI.
Being part of this visionary program will enable us to:
✅ Explore impactful collaborations with Moroccan and African hospitals, oncologists, and investors.
✅ Build new partnerships to bring the latest innovations in healthcare to patients across Africa.
✅ Accelerate our mission to ensure that every cancer patient, has access to personalized life-saving treatments powered by our cutting-edge solutions.
Grant by Bpifrance
14 June 2024
We are pleased to announce that Rosetta Omics has received the Bpifrance grant : BFT emergence to finance its deeptech program: two POCs studies in two solid tumors. BFT Emergence is a non-dilutive grant directed for deeptech startups to allow for the maximum financing of its R&D programs to reach the market. It is granted after a rigorous due diligence process of many months. The grant is part of the Deeptech plan financed by the France 2030 Program launched by the French State.
Accepted at Agoranov Incubator
May 2024
We are thrilled to announce that Rosetta Omics has been accepted into the prestigious Agoranov incubator in Paris! 🎉 This is a significant milestone for our startup, and we couldn’t be more excited about the opportunities that lie ahead. Agoranov is renowned for nurturing and propelling innovative companies like ours, and we are honored to be a part of their vibrant ecosystem. As we embark on this new chapter of our journey, we are deeply grateful for the support and encouragement from our team, advisors, and partners who have been instrumental in getting us to this point. At Rosetta Omics, we are dedicated to revolutionizing the field of oncology precision medicine . With Agoranov’s invaluable resources, mentorship, and network, we are confident that we will accelerate our growth and make a lasting impact in the healthcare industry. A heartfelt thank you to the Agoranov team for believing in our vision and giving us this incredible opportunity. We can’t wait to collaborate, learn, and innovate together.
HealthTech Innovation Days pitch competitions
After careful deliberation by our jury following four highly successful pitch sessions, we are thrilled to announce that Rosetta Omics is the 3rd WINNER in the history of HTID pitch competitions, prizes awarded by Damien Catoir! 🎉
We also want to congratulate MIRA vision for securing second place and Allegro Biotech for taking third place. A big thank you to all the companies that participated—your innovative ideas and hard work made this pitch sessions truly exceptional!
OncoEntrepreneur program
2023
Happy to be part of the OncoEntrepreneur program and being supported by Paris Saclay Cancer Cluster (PSCC) Cancer Campus
Nouzha Mohellibi Lucia ROBERT
Since January, 16 biotech, medtech and e-health projects (pre-creation or young start-ups) led by researchers, clinicians, entrepreneurs and students have been benefiting from the hashtagOncoEntrepreneur and hashtagOncoDigital programs.
The goal? To provide these emerging projects with the keys to a successful launch and to help them anticipate the stages of their development. The program includes more than 20 master classes throughout the first half of 2023.
The Paris-Saclay Cancer Cluster relies on programs initiated by Cancer Campus and which are part of the OncoSTART consortium. The ambition of these programs is to accelerate the development in France of innovative projects dedicated to the fight against cancer.
Elected to be the Executive Board Member at the Paris Saclay Cancer Cluster (PSCC)
2023
We are happy to announce that our CEO Dr. Wahid Awad, Ph.D., MBA has been elected as an Executive Board Member (Membre exécutif du conseil administratif) at the Paris-Saclay Cancer Cluster (PSCC)! Dr. Awad is representing the PME (SMEs) of pharma, biotech, medtech, and diagnostics companies in the executive office of PSCC (bureau exécutif). Founded to accelerate innovation in oncology, the Paris-Saclay Cancer Cluster brings together academia, industry, and healthcare institutions to foster collaboration and drive breakthroughs in cancer prevention, diagnosis, and treatment. Its mission is to position France as a global leader in cancer research, innovation, and therapeutic development, strengthening its role as a hub for translational medicine and cutting-edge healthcare solutions.
incubation program at ESCP Business School Blue Factory ESCP
2022
Happy to be part this incubation program at ESCP Business School Blue Factory ESCP and to and to meet and connect with many brilliant entrepreneurs.
Thank you Maeva Tordo and Manuella Ndoung